Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atrasentan - Chinook Therapeutics

Next Previous
Drug Profile

Atrasentan - Chinook Therapeutics

Alternative Names: A 147627; A-1476271; Abbott 147627; ABT-147627; ABT-627; Atrasentan hydrochloride; CHK-01; EXV-811; Vanrafia; Xinlay

Latest Information Update: 31 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; Chinook Therapeutics
  • Class Amides; Anti-inflammatories; Antineoplastics; Benzodioxoles; Carboxylic acids; Ethers; Heart failure therapies; Pyrrolidines; Small molecules; Toluenes; Vascular disorder therapies
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nephrotic syndrome; IgA nephropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed IgA nephropathy
  • Phase III Atherosclerosis
  • Phase II Diabetic nephropathies; Focal segmental glomerulosclerosis; Hereditary nephritis
  • Discontinued Adenocarcinoma; Brain cancer; Coronary artery restenosis; Heart failure; Lung cancer; Ovarian cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 27 Mar 2026 Novartis Pharmaceuticals plans a phase III for IgA nephropathy (In children, In adolescents, Treatment-experienced) (PO), in October 2026 (NCT07498335)
  • 13 Feb 2026 Novartis plans to submit for traditional approval for IgA Nephropathy in 2026
  • 13 Feb 2026 Final efficacy and adverse events data from a phase III ALIGN trial in IgA nephropathy released by Novartis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top